- Home
- XAIR vs SXTP Comparison
XAIR vs SXTP Comparison
Compare XAIR & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | SXTP |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.6M |
| IPO Year | 2015 | 2023 |
Fundamental Metrics
Financial Performance| Metric | XAIR | SXTP |
|---|---|---|
| Price | $2.59 | $1.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $20.00 | $3.70 |
| AVG Volume (30 Days) | 60.4K | ★ 87.1K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.77 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,679,000.00 | $1,005,471.00 |
| Revenue This Year | $4.23 | N/A |
| Revenue Next Year | $108.84 | $70.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 107.26 | 65.49 |
| 52 Week Low | $0.33 | $0.34 |
| 52 Week High | $8.19 | $8.62 |
Technical Indicators
Market Signals| Indicator | XAIR | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 35.95 | 48.77 |
| Support Level | $2.38 | $1.05 |
| Resistance Level | $2.66 | $1.66 |
| Average True Range (ATR) | 0.23 | 0.14 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 27.73 | 32.10 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.